Click here to get full coverage on FDMT Oct 2026 13.000 call (FDMT261016C00013000) stock price, news, quote and history - Yahoo Finance Singapore

FDMT Oct 2026 13.000 call (FDMT261016C00013000) stock price, news, quote and history  Yahoo Finance Singapore

FDMT Oct 2026 13.000 call (FDMT261016C00013000) stock price, news, quote and history - Yahoo Finance Singapore

Click here to get full coverage on 4D Molecular Therapeutics, Inc. $FDMT Shares Sold by Assenagon Asset Management S.A. - MarketBeat

4D Molecular Therapeutics, Inc. $FDMT Shares Sold by Assenagon Asset Management S.A.  MarketBeat

4D Molecular Therapeutics, Inc. $FDMT Shares Sold by Assenagon Asset Management S.A. - MarketBeat

Click here to get full coverage on FDMT SEC Filings - 4D Molecular Therapeutics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

FDMT SEC Filings - 4D Molecular Therapeutics Inc. 10-K, 10-Q, 8-K Forms  Stock Titan

FDMT SEC Filings - 4D Molecular Therapeutics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Click here to get full coverage on FDMT Stock: Jefferies Lowers Price Target to $21, Maintains Buy - GuruFocus

FDMT Stock: Jefferies Lowers Price Target to $21, Maintains Buy  GuruFocus

FDMT Stock: Jefferies Lowers Price Target to $21, Maintains Buy - GuruFocus

Click here to get full coverage on 4D Molecular Therapeutics Inc (FDMT) Stock Price Quote Today & Current Price Chart - Capital.com

4D Molecular Therapeutics Inc (FDMT) Stock Price Quote Today & Current Price Chart  Capital.com

4D Molecular Therapeutics Inc (FDMT) Stock Price Quote Today & Current Price Chart - Capital.com

Click here to get full coverage on 4D Molecular Therapeutics (FDMT) Q4 Profit Challenges Longstanding Loss Narrative - simplywall.st

4D Molecular Therapeutics (FDMT) Q4 Profit Challenges Longstanding Loss Narrative  simplywall.st

4D Molecular Therapeutics (FDMT) Q4 Profit Challenges Longstanding Loss Narrative - simplywall.st

Click here to get full coverage on 4D Molecular Therapeutics (NASDAQ: FDMT) elevates CFO Kristian Humer to Principal Accounting Officer - Stock Titan

4D Molecular Therapeutics (NASDAQ: FDMT) elevates CFO Kristian Humer to Principal Accounting Officer  Stock Titan

4D Molecular Therapeutics (NASDAQ: FDMT) elevates CFO Kristian Humer to Principal Accounting Officer - Stock Titan

Click here to get full coverage on FDMT Apr 2026 4.000 put (FDMT260417P00004000) interactive stock chart - Yahoo Finance Singapore

FDMT Apr 2026 4.000 put (FDMT260417P00004000) interactive stock chart  Yahoo Finance Singapore

FDMT Apr 2026 4.000 put (FDMT260417P00004000) interactive stock chart - Yahoo Finance Singapore

Click here to get full coverage on Latest FDMT News - 4DMT Reports Full Year 2025 Financial Resul... - Stock Titan

Latest FDMT News - 4DMT Reports Full Year 2025 Financial Resul...  Stock Titan

Latest FDMT News - 4DMT Reports Full Year 2025 Financial Resul... - Stock Titan

Click here to get full coverage on 4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates - Yahoo Finance

4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates  Yahoo Finance

4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates - Yahoo Finance

Click here to get full coverage on Biotech 4D Molecular Therapeutics lines up March investor conference talks - Stock Titan

Biotech 4D Molecular Therapeutics lines up March investor conference talks  Stock Titan

Biotech 4D Molecular Therapeutics lines up March investor conference talks - Stock Titan

Click here to get full coverage on FDMT Apr 2026 12.500 call (FDMT260417C00012500) Stock Historical Prices & Data - Yahoo! Finance Canada

FDMT Apr 2026 12.500 call (FDMT260417C00012500) Stock Historical Prices & Data  Yahoo! Finance Canada

FDMT Apr 2026 12.500 call (FDMT260417C00012500) Stock Historical Prices & Data - Yahoo! Finance Canada

Click here to get full coverage on 4D Molecular (NASDAQ: FDMT) awards 219,000 stock options to company officer - Stock Titan

4D Molecular (NASDAQ: FDMT) awards 219,000 stock options to company officer  Stock Titan

4D Molecular (NASDAQ: FDMT) awards 219,000 stock options to company officer - Stock Titan

Click here to get full coverage on Where is 4D Molecular Therapeutics (FDMT) Headed According to the Street? - Yahoo Finance

Where is 4D Molecular Therapeutics (FDMT) Headed According to the Street?  Yahoo Finance

Where is 4D Molecular Therapeutics (FDMT) Headed According to the Street? - Yahoo Finance

Click here to get full coverage on CEO at 4D Molecular (NASDAQ: FDMT) awarded 750K stock options - Stock Titan

CEO at 4D Molecular (NASDAQ: FDMT) awarded 750K stock options  Stock Titan

CEO at 4D Molecular (NASDAQ: FDMT) awarded 750K stock options - Stock Titan

Click here to get full coverage on Why Everyone Is Watching 4D Molecular Therapeutics, Inc. (FDMT) Closely - Yahoo Finance

Why Everyone Is Watching 4D Molecular Therapeutics, Inc. (FDMT) Closely  Yahoo Finance

Why Everyone Is Watching 4D Molecular Therapeutics, Inc. (FDMT) Closely - Yahoo Finance

Click here to get full coverage on 4D Molecular (NASDAQ: FDMT) awards 217,000 stock options to CLO - Stock Titan

4D Molecular (NASDAQ: FDMT) awards 217,000 stock options to CLO  Stock Titan

4D Molecular (NASDAQ: FDMT) awards 217,000 stock options to CLO - Stock Titan

Click here to get full coverage on FDMT Apr 2026 11.000 call (FDMT260417C00011000) Interactive Stock Chart - Yahoo! Finance Canada

FDMT Apr 2026 11.000 call (FDMT260417C00011000) Interactive Stock Chart  Yahoo! Finance Canada

FDMT Apr 2026 11.000 call (FDMT260417C00011000) Interactive Stock Chart - Yahoo! Finance Canada

Click here to get full coverage on Is 4D Molecular Therapeutics (NASDAQ:FDMT) In A Good Position To Invest In Growth? - Yahoo Finance

Is 4D Molecular Therapeutics (NASDAQ:FDMT) In A Good Position To Invest In Growth?  Yahoo Finance

Is 4D Molecular Therapeutics (NASDAQ:FDMT) In A Good Position To Invest In Growth? - Yahoo Finance

Click here to get full coverage on 4D Molecular Therapeutics appoints Kristian Humer as Principal Accounting Officer - TradingView

4D Molecular Therapeutics appoints Kristian Humer as Principal Accounting Officer  TradingView

4D Molecular Therapeutics appoints Kristian Humer as Principal Accounting Officer - TradingView

Click here to get full coverage on 4D Molecular Therapeutics, Inc.'s (NASDAQ:FDMT) institutional investors lost 20% over the past week but have profited from longer-term gains - Yahoo Finance

4D Molecular Therapeutics, Inc.'s (NASDAQ:FDMT) institutional investors lost 20% over the past week but have profited from longer-term gains  Yahoo Finance

4D Molecular Therapeutics, Inc.'s (NASDAQ:FDMT) institutional investors lost 20% over the past week but have profited from longer-term gains - Yahoo Finance

Click here to get full coverage on Vanguard amendment shows 0 shares of 4D Molecular (NASDAQ: FDMT) - Stock Titan

Vanguard amendment shows 0 shares of 4D Molecular (NASDAQ: FDMT)  Stock Titan

Vanguard amendment shows 0 shares of 4D Molecular (NASDAQ: FDMT) - Stock Titan

Click here to get full coverage on One biotech’s 2026 push to change treatment for wet AMD and DME - Stock Titan

One biotech’s 2026 push to change treatment for wet AMD and DME  Stock Titan

One biotech’s 2026 push to change treatment for wet AMD and DME - Stock Titan

Click here to get full coverage on 4DMT fills pivotal eye-disease trial early, setting up 2027 readout - Stock Titan

4DMT fills pivotal eye-disease trial early, setting up 2027 readout  Stock Titan

4DMT fills pivotal eye-disease trial early, setting up 2027 readout - Stock Titan

Click here to get full coverage on 4D Molecular (NASDAQ: FDMT) VP uses share sale to cover taxes - Stock Titan

4D Molecular (NASDAQ: FDMT) VP uses share sale to cover taxes  Stock Titan

4D Molecular (NASDAQ: FDMT) VP uses share sale to cover taxes - Stock Titan

Click here to get full coverage on 4D Molecular to layoff about 25% of workforce - MSN

4D Molecular to layoff about 25% of workforce  MSN

4D Molecular to layoff about 25% of workforce - MSN

Click here to get full coverage on Barclays Flags M&A Tailwinds and Pricing Relief as Upside Catalysts for 4D Molecular Therapeutics, Inc. (FDMT) - Yahoo Finance

Barclays Flags M&A Tailwinds and Pricing Relief as Upside Catalysts for 4D Molecular Therapeutics, Inc. (FDMT)  Yahoo Finance

Barclays Flags M&A Tailwinds and Pricing Relief as Upside Catalysts for 4D Molecular Therapeutics, Inc. (FDMT) - Yahoo Finance

Click here to get full coverage on 4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance

4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates  Yahoo Finance

4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance

Click here to get full coverage on 4D Molecular Therapeutics (NASDAQ: FDMT) posts 2025 results, inks Otsuka deal, extends cash runway - Stock Titan

4D Molecular Therapeutics (NASDAQ: FDMT) posts 2025 results, inks Otsuka deal, extends cash runway  Stock Titan

4D Molecular Therapeutics (NASDAQ: FDMT) posts 2025 results, inks Otsuka deal, extends cash runway - Stock Titan

Click here to get full coverage on 4D Molecular Therapeutics (NASDAQ:FDMT) Trading 8.7% Higher - Here's Why - MarketBeat

4D Molecular Therapeutics (NASDAQ:FDMT) Trading 8.7% Higher - Here's Why  MarketBeat

4D Molecular Therapeutics (NASDAQ:FDMT) Trading 8.7% Higher - Here's Why - MarketBeat

Click here to get full coverage on Biotech 4DMT hands 23,600 stock units to four new hires under award plan - Stock Titan

Biotech 4DMT hands 23,600 stock units to four new hires under award plan  Stock Titan

Biotech 4DMT hands 23,600 stock units to four new hires under award plan - Stock Titan

Click here to get full coverage on FDMT: Chardan Capital Maintains Buy Rating with Price Target of $26.00 | FDMT Stock News - GuruFocus

FDMT: Chardan Capital Maintains Buy Rating with Price Target of $26.00 | FDMT Stock News  GuruFocus

FDMT: Chardan Capital Maintains Buy Rating with Price Target of $26.00 | FDMT Stock News - GuruFocus

Click here to get full coverage on Jefferies Initiates 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Announces Target Price $21 - 富途牛牛

Jefferies Initiates 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Announces Target Price $21  富途牛牛

Jefferies Initiates 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Announces Target Price $21 - 富途牛牛

Click here to get full coverage on VP Gupta of 4d molecular sold $3357 in FDMT stock - investing.com

VP Gupta of 4d molecular sold $3357 in FDMT stock  investing.com

VP Gupta of 4d molecular sold $3357 in FDMT stock - investing.com

Click here to get full coverage on Biotech 4DMT hands 124,200 stock units to just nine recruits - Stock Titan

Biotech 4DMT hands 124,200 stock units to just nine recruits  Stock Titan

Biotech 4DMT hands 124,200 stock units to just nine recruits - Stock Titan

Click here to get full coverage on FDMT: 2025 revenue jumped to $85.2M on Otsuka deal; net loss narrowed, cash at $514M, pipeline advanced - TradingView

FDMT: 2025 revenue jumped to $85.2M on Otsuka deal; net loss narrowed, cash at $514M, pipeline advanced  TradingView

FDMT: 2025 revenue jumped to $85.2M on Otsuka deal; net loss narrowed, cash at $514M, pipeline advanced - TradingView

Click here to get full coverage on 4D Molecular Therapeutics, Inc. (FDMT) Q4 Results Surpass Forecasts for Earnings and Revenue - Bitget

4D Molecular Therapeutics, Inc. (FDMT) Q4 Results Surpass Forecasts for Earnings and Revenue  Bitget

4D Molecular Therapeutics, Inc. (FDMT) Q4 Results Surpass Forecasts for Earnings and Revenue - Bitget

Click here to get full coverage on 4D Molecular Therapeutics: Jury Still Out On CF Gene Therapy After Dense Data Drop (NASDAQ:FDMT) - Seeking Alpha

4D Molecular Therapeutics: Jury Still Out On CF Gene Therapy After Dense Data Drop (NASDAQ:FDMT)  Seeking Alpha

4D Molecular Therapeutics: Jury Still Out On CF Gene Therapy After Dense Data Drop (NASDAQ:FDMT) - Seeking Alpha

Click here to get full coverage on Institutional investors own a significant stake of 49% in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - simplywall.st

Institutional investors own a significant stake of 49% in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)  simplywall.st

Institutional investors own a significant stake of 49% in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - simplywall.st

Click here to get full coverage on 4D Molecular Therapeutics (FDMT) Receives a Hold from Cantor Fitzgerald - The Globe and Mail

4D Molecular Therapeutics (FDMT) Receives a Hold from Cantor Fitzgerald  The Globe and Mail

4D Molecular Therapeutics (FDMT) Receives a Hold from Cantor Fitzgerald - The Globe and Mail

Click here to get full coverage on Technical Reactions to FDMT Trends in Macro Strategies - Stock Traders Daily

Technical Reactions to FDMT Trends in Macro Strategies  Stock Traders Daily

Technical Reactions to FDMT Trends in Macro Strategies - Stock Traders Daily

Click here to get full coverage on New Analyst Forecast: $FDMT Given $33 Price Target - Quiver Quantitative

New Analyst Forecast: $FDMT Given $33 Price Target  Quiver Quantitative

New Analyst Forecast: $FDMT Given $33 Price Target - Quiver Quantitative

Click here to get full coverage on FDMT Jul 2026 12.000 call (FDMT260717C00012000) stock historical prices and data - Yahoo Finance UK

FDMT Jul 2026 12.000 call (FDMT260717C00012000) stock historical prices and data  Yahoo Finance UK

FDMT Jul 2026 12.000 call (FDMT260717C00012000) stock historical prices and data - Yahoo Finance UK

Click here to get full coverage on Key facts: 4D Molecular positive data; 4D710 P2; 25% cuts; RBC PT $35 - TradingView

Key facts: 4D Molecular positive data; 4D710 P2; 25% cuts; RBC PT $35  TradingView

Key facts: 4D Molecular positive data; 4D710 P2; 25% cuts; RBC PT $35 - TradingView

Click here to get full coverage on 4D Molecular Therapeutics Appoints Kristian Humer as Chief Financial Officer - Quiver Quantitative

4D Molecular Therapeutics Appoints Kristian Humer as Chief Financial Officer  Quiver Quantitative

4D Molecular Therapeutics Appoints Kristian Humer as Chief Financial Officer - Quiver Quantitative

Click here to get full coverage on 4D Molecular Therapeutics Consolidates Financial Leadership Under New Role - TipRanks

4D Molecular Therapeutics Consolidates Financial Leadership Under New Role  TipRanks

4D Molecular Therapeutics Consolidates Financial Leadership Under New Role - TipRanks

Click here to get full coverage on 4D Molecular Therapeutics: This Gene Therapy Company May Soon Surprise Investors (NASDAQ:FDMT) - Seeking Alpha

4D Molecular Therapeutics: This Gene Therapy Company May Soon Surprise Investors (NASDAQ:FDMT)  Seeking Alpha

4D Molecular Therapeutics: This Gene Therapy Company May Soon Surprise Investors (NASDAQ:FDMT) - Seeking Alpha

Click here to get full coverage on 4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones - GlobeNewswire

4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones  GlobeNewswire

4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones - GlobeNewswire

Click here to get full coverage on 4D Molecular (FDMT) Grants RSUs to New Employees - GuruFocus

4D Molecular (FDMT) Grants RSUs to New Employees  GuruFocus

4D Molecular (FDMT) Grants RSUs to New Employees - GuruFocus

Click here to get full coverage on 4DMT to Participate in Upcoming Investor Meetings - GlobeNewswire

4DMT to Participate in Upcoming Investor Meetings  GlobeNewswire

4DMT to Participate in Upcoming Investor Meetings - GlobeNewswire

Click here to get full coverage on 4D Molecular Therapeutics, Inc. Common Stock (FDMT) Stock Price Today & Analysis - Gotrade

4D Molecular Therapeutics, Inc. Common Stock (FDMT) Stock Price Today & Analysis  Gotrade

4D Molecular Therapeutics, Inc. Common Stock (FDMT) Stock Price Today & Analysis - Gotrade

Click here to get full coverage on FDMT Stock Gains Pre-Market After Positive Study Data For Experimental Drug In Eye Disease - Stocktwits

FDMT Stock Gains Pre-Market After Positive Study Data For Experimental Drug In Eye Disease  Stocktwits

FDMT Stock Gains Pre-Market After Positive Study Data For Experimental Drug In Eye Disease - Stocktwits

Click here to get full coverage on 4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones - ChartMill

4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones  ChartMill

4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones - ChartMill

Click here to get full coverage on Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Scholar Rock Holding (SRRK) and Acrivon Therapeutics, Inc. (ACRV) - The Globe and Mail

Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Scholar Rock Holding (SRRK) and Acrivon Therapeutics, Inc. (ACRV)  The Globe and Mail

Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Scholar Rock Holding (SRRK) and Acrivon Therapeutics, Inc. (ACRV) - The Globe and Mail

Click here to get full coverage on 4D Molecular posts Phase 1 trial data for cystic fibrosis drug - Seeking Alpha

4D Molecular posts Phase 1 trial data for cystic fibrosis drug  Seeking Alpha

4D Molecular posts Phase 1 trial data for cystic fibrosis drug - Seeking Alpha

Click here to get full coverage on We Think 4D Molecular Therapeutics (NASDAQ:FDMT) Can Afford To Drive Business Growth - 富途牛牛

We Think 4D Molecular Therapeutics (NASDAQ:FDMT) Can Afford To Drive Business Growth  富途牛牛

We Think 4D Molecular Therapeutics (NASDAQ:FDMT) Can Afford To Drive Business Growth - 富途牛牛

Click here to get full coverage on Is 4D Molecular Therapeutics Stock Built to Withstand More Downside? - Trefis

Is 4D Molecular Therapeutics Stock Built to Withstand More Downside?  Trefis

Is 4D Molecular Therapeutics Stock Built to Withstand More Downside? - Trefis

Click here to get full coverage on 4D Molecular Therapeutics Inc : Jefferies Ass - Moomoo

4D Molecular Therapeutics Inc : Jefferies Ass  Moomoo

4D Molecular Therapeutics Inc : Jefferies Ass - Moomoo

Click here to get full coverage on 4D Molecular Therapeutics Advances 4D-150 Phase 3 Program in Wet AMD, Accelerates Data Readout to H1 2027 - Quiver Quantitative

4D Molecular Therapeutics Advances 4D-150 Phase 3 Program in Wet AMD, Accelerates Data Readout to H1 2027  Quiver Quantitative

4D Molecular Therapeutics Advances 4D-150 Phase 3 Program in Wet AMD, Accelerates Data Readout to H1 2027 - Quiver Quantitative

Click here to get full coverage on 4D Molecular Therapeutics 10-K: $85.2M collaboration revenue; improved net loss $140.1M - TradingView

4D Molecular Therapeutics 10-K: $85.2M collaboration revenue; improved net loss $140.1M  TradingView

4D Molecular Therapeutics 10-K: $85.2M collaboration revenue; improved net loss $140.1M - TradingView

Click here to get full coverage on (FDMT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily

(FDMT) Price Dynamics and Execution-Aware Positioning  Stock Traders Daily

(FDMT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily

Click here to get full coverage on 4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire

4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants  GlobeNewswire

4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire

Click here to get full coverage on Cantor Fitzgerald Maintains 4D Molecular Therapeutics(FDMT.US) With Hold Rating - 富途牛牛

Cantor Fitzgerald Maintains 4D Molecular Therapeutics(FDMT.US) With Hold Rating  富途牛牛

Cantor Fitzgerald Maintains 4D Molecular Therapeutics(FDMT.US) With Hold Rating - 富途牛牛

Click here to get full coverage on 4D Molecular Therapeutics (FDMT) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat

4D Molecular Therapeutics (FDMT) FDA Approvals, PDUFA Dates & Drug Alerts 2026  MarketBeat

4D Molecular Therapeutics (FDMT) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat

Click here to get full coverage on Analysts Are Bullish on Top Healthcare Stocks: Novan (NOVN), 4D Molecular Therapeutics (FDMT) - The Globe and Mail

Analysts Are Bullish on Top Healthcare Stocks: Novan (NOVN), 4D Molecular Therapeutics (FDMT)  The Globe and Mail

Analysts Are Bullish on Top Healthcare Stocks: Novan (NOVN), 4D Molecular Therapeutics (FDMT) - The Globe and Mail

Click here to get full coverage on 4DMT Announces Exclusive License Agreement with Otsuka - GlobeNewswire

4DMT Announces Exclusive License Agreement with Otsuka  GlobeNewswire

4DMT Announces Exclusive License Agreement with Otsuka - GlobeNewswire

Click here to get full coverage on 4DMT Provides Company Update and Anticipated Development Milestones for 2026 - GlobeNewswire

4DMT Provides Company Update and Anticipated Development Milestones for 2026  GlobeNewswire

FDMT

Price Chart

Key Statistics

Technicals

About FDMT

Latest News

FDMT Oct 2026 13.000 call (FDMT261016C00013000) stock price, news, quote and history - Yahoo Finance Singapore

4D Molecular Therapeutics, Inc. $FDMT Shares Sold by Assenagon Asset Management S.A. - MarketBeat

FDMT SEC Filings - 4D Molecular Therapeutics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Advanced Charts

Top Gainers

Top Losers